AAVantgarde Bio
Last updated: November 14, 2025
CEO - Natalia Misciattelli
Country: Italy | Funding: $206.3M (+)
Founded: 2021
Website: https://www.aavantgarde.com/
AAVantgarde Bio is a clinical-stage biotechnology company that develops retinal disease gene therapies. One of its drugs is intended at patients with Stargardt disease, a leading cause of vision loss in children and young adults. By delivering the full-length ABCA4 protein, AAVantgarde hopes that it can address the root cause of this eye condition. Another asset is for patients with retinitis pigmentosa associated with Usher syndrome - rare genetic disease that affects both hearing and vision. AAVantgarde says that its proprietary technology has demonstrated high transduction, protein expression and safety for both Stargardt and Usher 1B.
Founded: 2021
Website: https://www.aavantgarde.com/
AAVantgarde Bio is a clinical-stage biotechnology company that develops retinal disease gene therapies. One of its drugs is intended at patients with Stargardt disease, a leading cause of vision loss in children and young adults. By delivering the full-length ABCA4 protein, AAVantgarde hopes that it can address the root cause of this eye condition. Another asset is for patients with retinitis pigmentosa associated with Usher syndrome - rare genetic disease that affects both hearing and vision. AAVantgarde says that its proprietary technology has demonstrated high transduction, protein expression and safety for both Stargardt and Usher 1B.
